



# NUCLEAR SOLUTIONS

A DIVISION OF THE TOMAYKO GROUP WWW.TOMAYKOGROUP.COM

December 5, 2006

Nuclear Regulatory Commission  
Tara Weidner, Health Physicist  
Region 1  
475 Allendale Road  
King of Prussia, PA 19406

J-9  
MS-16

RE: RML # 37-28520-01 Amendment 34, Control # 139619

03031697

Dear Ms. Weidner:

This letter is in response to your request for additional information regarding Dr. Ambrose. I have attached a copy of a letter from the Executive Director of the CBNC attesting to the certification of Dr. Jayaseelan Ambrose. I have also requested Dr. Ambrose to send me a copy of his certificate and a copy of his preceptor letter. As of this date I have not received either. As soon as I receive them I will forward them to you.

Please issue this amendment without adding Dr. Ambrose at this time if necessary. I don't want to delay adding all of the other physicians.

Please add Jerome M. Itzkoff, M.D. as an authorized user for materials and uses as defined by 10 CFR 35.100 and 35.200. I have attached proof of his qualifications, NRC RML# 37-14041-01.

Please add Jeffrey Mark Friedel, M.D. as an authorized user for materials and uses as defined by 10 CFR 35.200 (Cardiovascular Studies). I have attached proof of his qualifications, CBNC certificate # 3311 and a preceptor letter.

If you need anymore information please contact me at 412-427-9284 or 412-490-0302 ex 112.

Sincerely,




Donald Ashton, CNMT NCT

Executive Director

The Tomayko Group/TTG Nuclear Solutions

139619  
NMSS/RGN MATERIALS-002



## Certification Board of Nuclear Cardiology

19562 Club House Road • Montgomery Village, Maryland 20886

Tel: +240.631.8151 • Fax: +240.631.8152

[administration@cbnc.org](mailto:administration@cbnc.org) • [www.cbnc.org](http://www.cbnc.org)

### BOARD OF DIRECTORS

#### Representing the American Society of Nuclear Cardiology

James A. Arrighi, MD

Manuel D. Cerqueira, MD

Edward P. Ficaro, PhD

Robert J. Gropler, MD

Christopher L. Hansen, MD

Milena J. Henzlova, MD

Howard C. Lewin, MD

Sally Schwarz, RPh, MS, BCNP

William A. VanDecker, MD

#### Representing the American College of Cardiology

Kenneth A. Brown, MD

#### At Large Director

Olakunle O. Akinboboye, MD, MPH

### Verification of Certified Status

To Whom It May Concern:

This letter confirms that the following individual is certified in nuclear cardiology by the Certification Council of Nuclear Cardiology.

Name: Jayaseelan Ambrose, M.D.

Year of Certification: October 2004 (Valid Through December 2014)

Certificate No.: 3167

Attested by:

Dawn M. Edgerton, Executive Director

Date: November 7, 2006

Dawn M. Edgerton, MA  
Executive Director

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 2 PAGES

Amendment No. 7

Duplicate

MATERIALS LICENSE

Duplicate

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

## Licensee

In accordance with the letter dated  
September 8, 2004,

1. Medical Imaging Institute

3. License number 37-14041-01 is amended in  
its entirety to read as follows:

2. Centre Commons Building

4. Expiration date August 31, 2011

Suite #380

5. Docket No. 030-32132

5750 Centre Avenue

Reference No.

Pittsburgh, Pennsylvania 15206

6. Byproduct, source, and/or special  
nuclear material

Chemical and/or physical form

8. Maximum amount that licensee may  
possess at any one time under this  
licenseA. Any byproduct material  
permitted by 10 CFR 35.100

A. As needed

B. Any byproduct material  
permitted by 10 CFR 35.200

B. As needed

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

## CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities at Centre Commons Building, Suite 380, 5750 Centre Avenue, Pittsburgh, Pennsylvania.

11. The Radiation Safety Officer for this license is Mary Beth Farrell.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use:

Duplicate

Duplicate

Duplicate

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 2 PAGES

Duplicate  
MATERIALS LICENSE  
SUPPLEMENTARY SHEET

Duplicate

License Number

92-14041-01

Docket or Reference Number

030-32132

Amendment No. 7

Authorized UsersMaterial and Use

Richard L. Kalla, M.D.

35.100; 35.200

Shanteri U. Nayak, M.D.

35.100; 35.200

Jerome M. Itzkoff, M.D.

35.100; 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies to only those procedures that are required to be submitted in accordance with the regulations. Additionally, this condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letter dated June 21, 2001  
B. Letter dated August 5, 2002  
C. Letter dated April 15, 2003

For the U.S. Nuclear Regulatory Commission

Date November 19, 2004

By

*Original signed by Steven Courtemanche*

Steven Courtemanche  
Commercial and R&D Branch  
Division of Nuclear Materials Safety

Duplicate

Duplicate

Region I

King of Prussia, Pennsylvania 19406

Duplicate

# THE CERTIFICATION BOARD OF NUCLEAR CARDIOLOGY

Incorporated 1996

CERTIFIES THAT

*Jeffrey Mark Friedel, MD*

HAVING MET THE REQUIREMENTS PRESCRIBED BY THIS BOARD FOR PHYSICIANS RESIDING  
IN THE UNITED STATES AND HAVING SATISFACTORILY PASSED THE REQUIRED EXAMINATION,

IS HEREBY DESIGNATED


A DIPLOMATE CERTIFIED IN THE SUBSPECIALTY OF

**NUCLEAR CARDIOLOGY**


FOR THE PERIOD 2004 THROUGH 2014

*Manoel D. Cergueta*  
PRESIDENT

*R. J. ...*  
SECRETARY



CERTIFICATE # 3311



OCTOBER 24, 2004

**ALLEGHENY  
GENERAL HOSPITAL**

WEST PENN ALLEGHENY HEALTH SYSTEM

320 EAST NORTH AVENUE, PITTSBURGH, PA 15212-4772

412-359-3131

June 22, 2004

To: Certification board of Nuclear Cardiology

This is to confirm that Dr. Jeffrey Friedel has been under the department of nuclear cardiology's supervision and training in the performance of cardiac imaging for six months during his 3 year cardiology fellowship program from 7/1/00 to 6/30/03. He has interpreted more than 1700 nuclear cardiology studies using thallium and technetium radioisotopes. The studies include first pass right and left ventricular function, gated blood pool, and myocardial perfusion. Multiple myocardial perfusion protocols using both SPECT and planar imaging techniques are used in our laboratory. He has also correlated at least 30 myocardial perfusion studies with coronary angiograms.

Dr. Friedel has had actual hands on experience by performing the technical component of 35 studies. The experience includes: radiopharmaceutical preparation (including Tc-99m Generator elution and QC), dose administration, camera quality control, camera setup, image acquisition, and imaging processing. He has also interviewed, evaluated, and performed the stress test on over 400 patients using multiple exercise as well as pharmacologic protocols.

Dr. Friedel's has completed a fellowship training in nuclear cardiology that meets the requirements as outlined in the ACC/ASNC COCATS Guidelines (revised 2000).

Dr. Friedel has completed 1000 hours of clinical and work experience during his six months in our department. In addition he has completed 50 hours of classroom and laboratory training in radiation safety and radioisotope handling through a supplemental program thereby exceeding the NRC training requirements to be an authorized user of unsealed byproduct material as outline in The Code of Federal Regulations: Title 10, Part 35.290 paragraph (c)(1). **Dr. Friedel is competent to independently function as an authorized user under 10 CFR 35.290.**

In my judgement, Dr. Friedel has gained sufficient knowledge to order and administer nuclear cardiology radiopharmaceuticals and interpret a wide variety of nuclear cardiology images.

If you need any further information, please do not hesitate to contact to me.

Sincerely,

John Rehder, M.D., FACC  
Director, Nuclear Cardiology  
NRC License #: 37-01317-04